Nykode Therapeutics (NYKD.OL)

Executive Summary

Nykode Therapeutics is a clinical-stage Norwegian biopharmaceutical company advancing its proprietary Vaccibody™ platform, a modular immunotherapy technology designed to induce targeted immune responses against cancer and autoimmune diseases. The platform's unique design enables precise delivery of antigens and immunomodulators, offering potential advantages over traditional vaccine approaches. Founded in 2006 based on research from the University of Oslo, the company went public (ticker: NYKD.OL) and has since completed initial clinical studies in oncology and infectious disease, including Phase 1/2 trials for a DNA vaccine in high-grade cervical intraepithelial neoplasia, a COVID-19 vaccine, and a personalized neoantigen vaccine for solid tumors. These trials have demonstrated the platform's safety and immunogenicity, setting the stage for further development. Looking ahead, Nykode is poised to advance its lead candidates into later-stage trials and explore strategic partnerships to leverage its platform across multiple indications. The company's valuation of approximately $1.05 billion reflects market anticipation of upcoming data readouts and potential collaborations. Key near-term catalysts include the initiation of a Phase 2 trial for VB10.NEO in solid tumors, the release of long-term follow-up data from prior studies, and the announcement of a major pharma partnership for autoimmune disease applications. With a strong scientific foundation and a versatile platform, Nykode represents a compelling opportunity in the immuno-oncology and vaccine space, albeit with inherent clinical and commercial risks.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2 trial for VB10.NEO in solid tumors60% success
• H1 2026Long-term follow-up data from VB10.16 cervical cancer trial70% success
• 2026Partnership announcement for Vaccibody platform in autoimmune diseases50% success